MENUA Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies
Protocol
UMCC 2014.083
Purpose
This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.
UMCC Principal Investigator
Eligibility
Inclusion Criteria:
Male or female 18 years of age or older
Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed
Meet laboratory parameter requirements at study entry
Exclusion Criteria
Pregnancy or breast feeding
History of prior malignancy
Auto-immune hemolytic anemia
Acute Promyelocytic Leukemia
Uncontrolled and clinically significant disease-related metabolic disorder
Other serious illness or medical conditions
Patients who have exhibited allergic reactions to compounds structurally similar to APTO-253 HCl
For more information go to clinicaltrials.gov